At yesterday’s trading Pfizer shares rose by 4.6%. This was facilitated by the fact that the corporation bought the biotechnology company Arena Pharmaceuticals, paying $100 for each share. The total amount of the deal is 6.7 billion dollars. After the publication of this news in the media, the shares of the company, which is engaged in developments in the field of immunology and treatment of inflammation rose in price by 100%.

Biotechnology corporation Arena Pharmaceuticals is engaged in the development of drugs that are used in cardiology, dermatology, as well as gastroenterology. Analysts believe that it is the drug called Etrasimod, which is currently undergoing trials for efficacy, that has caught Pfizer’s attention. If it is approved, Pfizer will be able to compete with many pharma giants that create drugs to treat ulcerative colitis and related inflammatory diseases.

 Pfizer’s stock will be an attractive pharmaceutical investment next year if the company consistently brings new drugs to market and maintains user confidence.